

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A01N 37/16, 59/00, 25/22, A61L 2/18, C07C 409/24	A1	(11) International Publication Number: WO 94/15465 (43) International Publication Date: 21 July 1994 (21.07.94)
(21) International Application Number: PCT/GB94/00010 (22) International Filing Date: 5 January 1994 (05.01.94) (30) Priority Data: 9300366.3 9 January 1993 (09.01.93) GB (71) Applicant (for all designated States except US): SOLVAY INTEROX LIMITED [GB/GB]; Baronet Works, Baronet Road, Warrington, Cheshire WA4 6HB (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): MALONE, Joseph, William, Gerard [GB/GB]; 33 Church Road Roby, Liverpool L36 9TL (GB). (74) Agent: PEARCE, Timothy; Solvay Interox Limited, Patent De- partment, P.O. Box 51, Moorfield Road, Widnes, Cheshire WA8 OFE (GB).	(81) Designated States: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.	
(54) Title: COMPOSITIONS AND USES THEREOF (57) Abstract <p>An aqueous composition comprising a lower aliphatic peracid, a corrosion inhibitor and a peroxide stabilizer and/or peracid stabilizer, is useful for disinfecting medical equipment, particularly metal components of such equipment. A process for obtaining such compositions is also provided and comprises mixing a first aqueous solution comprising a lower aliphatic peracid with a second aqueous solution comprising hydrogen peroxide, a corrosion inhibitor and a hydrogen peroxide stabiliser and/or a peracid stabiliser. The first and second aqueous solutions can form a two pack system for obtaining such compositions.</p> <p>→ Two pack system → solutions stable for 1 week (use sol.) CEL 94 1994 → Medical Instrument</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

5

10

Compositions and uses thereof

This invention concerns compositions, processes for the preparation of such compositions, two-pack systems for preparing such compositions and
15 uses of such compositions. More particularly the present invention concerns compositions comprising dilute aqueous solutions of lower aliphatic peracids and their use as disinfectant compositions.

The lower aliphatic peracids are effective wide-spectrum bactericides which have the particular advantage, in use, of leaving as residues only the
20 corresponding lower aliphatic acids and therefore being particularly suitable for applications which require a non-environmentally-polluting disinfectant. While the lower aliphatic peracids in general are contemplated herein, for example those corresponding to carboxylic aliphatic acids containing 2 to 9 carbon atoms, peracetic acid is particularly envisaged since it is already a
25 commercially important peracid for disinfectant purposes. Where the following description relates to peracetic acid it is to be understood that the other peracids may be read in substitution therefor provided that the technical context allows it.

Aqueous solutions of peracetic acid containing up to about 45% by
30 weight of peracetic acid are commercially available. Such solutions may be produced by reacting appropriately concentrated hydrogen peroxide and acetic acid in an aqueous medium in the presence of an acid catalyst which is usually sulphuric acid or other strong mineral acid. The acid catalyst may be present in from about 0.1% to about 5% by weight of the reaction
35 mixture.

Aqueous solutions of peracetic acid represent equilibrium mixtures of the reactants and the reaction products and, under relatively forcing reaction conditions, for example when using one or more of a substantial quantity of

catalyst, an elevated reaction temperature and a concentrated reaction mixture, equilibrium may be substantially reached in a relatively short time. When using the strong acid catalyst in from 2% to 5% of the reaction mixture, a temperature of from 30°C to 50°C and a concentration of acid
5 above about 20% by weight the reaction mixture may come to equilibrium within hours. For some applications, or where long storage is envisaged, it may not be desirable for there to be catalyst residues in a peracid product and particularly, for example, in dilute products intended for personal or domestic hygiene use. For many applications dilute solutions of peracetic
10 acid, for example below 5% by weight but often below 2%, for example from 0.1% to 2% by weight, are required. Concentrations of peracetic acid above 0.5% by weight for example from 0.5% to 1% by weight, are particularly effective bactericidally in, for example, toilet cleansing applications. Such dilute peracetic acid solutions may be produced directly
15 by reacting acetic acid and hydrogen peroxide in a suitably dilute reaction medium but equilibrium can take an extremely long time to reach, particularly at the more extreme dilutions envisaged. At peracid concentrations below 1% by weight, equilibrium may take a month or more to reach if the reaction is not acid catalysed or a week or more even if the
20 reaction is acid catalysed. This entails a very heavy utilisation of plant and equipment on a large production scale.

If a concentrated equilibrium solution of peracetic acid is diluted with water, the equilibrium point of the system is progressively altered, as dilution progresses, in favour of the regeneration of the original reactants.
25 The ageing time taken to attain the new equilibrium point, after dilution, is of a similar order to that required to produce such a dilute solution directly from suitable reactants. Such a diluted solution may be used directly, although it is not at equilibrium and is therefore of variable composition in storage. Such non-equilibrium diluted solutions also have a composition
30 dictated by the equilibrium point applying at the original concentration, which may not be desired in some applications.

In 1955 Greenspan et al. (Proc. 42nd Ann. Mtg. Chem. Spec. Man. Ass. Dec. 1955), disclosed that stable dilute peracetic acid solutions can be prepared by the use of peracid stabilisers in conjunction with proper
35 adjustment of the relative concentrations of the components of the dilute peracid solution, that is to say that, if the prepared dilute solution is not fully at equilibrium, adjustment of the balance of the components can achieve stability. The solutions in question may be prepared by dilution of

commercial, e.g. fully equilibrated peracetic acid which has been produced by the use of small amounts of a mineral acid catalyst.

United States Patent No 4297298 describes the production of an aqueous solution of a lower aliphatic peracid by preparing in a first process step a concentrated solution of the peracid from the corresponding carboxylic acid or anhydride and concentrated hydrogen peroxide in the presence of a small quantity of a strong acid catalyst and diluting the solution with a solution containing at least one of the reagents from the first process step so as to bring the concentration of the aliphatic peracid to the rated concentration of the mixture the concentration of the diluent reagent or reagents being chosen "so that once dilution has been brought about, the system is no longer at equilibrium, but tends to move in the direction of forming further aliphatic peracid at a very slow rate." The process specifically described in United States Patent No. 4297298 produces a non-equilibrium composition which contains an extremely high concentration of hydrogen peroxide, e.g. from 28% to 46%. Such a concentration on contact with the user would cause skin bleaching and pain.

United States Patent No. 4743447 describes the production of solutions having a hydrogen peroxide base for disinfecting contact lenses, the solution having from 0.005% to 0.1% by weight of peracetic acid, 1% to 8% by weight of hydrogen peroxide and sufficient acetic acid for the system to reach equilibrium. Such a solution may be prepared by direct reaction using a very dilute reaction mixture with lengthy equilibration or from a stable commercial solution having a "weak concentration" of peracetic acid to which the other constituents of the composition are added. This teaching does not therefore avoid the separate initial step of producing a stable weak solution of peracetic acid from which to produce in turn the final product.

EP-A-0357238 (Steris Corp) discloses an anti-microbial composition comprising a strong oxidant, a copper and brass corrosion inhibitor, a buffering agent, at least one anti-corrosive agent which exhibits corrosion inhibition in at least aluminium, carbon steel and stainless steel, and a wetting agent. The corrosion inhibitors specifically disclosed for brass and aluminium comprise triazoles and molybdates, which are known to have unfavourable toxicity, and which therefore renders undesirable their use in a medical environment.

In certain cases, it is desirable for the peracetic acid composition employed as a disinfectant composition to be produced by dilution of a more

concentrated peracetic acid solution with a second solution which can comprise components which may confer beneficial properties on the peracetic acid composition, such as corrosion inhibitors. In the absence of any counter measures, or even despite them, it is possible that the second
5 solution can become contaminated with micro-organisms, for example, moulds and yeasts, during storage prior to mixing with the peracetic acid solution. Control of this is therefore desirable, but many of the compounds commonly recommended for such control are either incompatible with peracetic acid, or can be undesirable for medical use because of their
10 toxicity.

It is an object of the present invention to provide a disinfectant composition, based on a dilute solution of peracid, which may be used on medical equipment comprising metal components to be disinfected.

It is a further object of certain embodiments of the present invention to
15 provide a solution suitable for diluting peracetic acid to produce a composition which may be used on medical equipment comprising metal components, such solution having improved resistance to contamination by micro-organisms.

In accordance with the present invention there is provided a process for
20 the preparation of an aqueous disinfectant composition characterised in that the process comprises mixing a first aqueous solution comprising a lower aliphatic peracid with a second aqueous solution comprising hydrogen peroxide, a corrosion inhibitor and a hydrogen peroxide stabilizer and/or peracid stabilizer.

25 In another aspect, the present invention provides a disinfectant composition obtainable by a process comprising mixing a first aqueous solution comprising a lower aliphatic peracid with a second aqueous solution comprising hydrogen peroxide, a corrosion inhibitor and a hydrogen peroxide stabilizer and/or peracid stabilizer. It is to be understood that the peracid
30 composition of the present invention is not in equilibrium and comprises a relatively higher concentration of stabilizer(s) than a skilled person would expect to find in a composition which is in equilibrium and comprises a similar concentration of peracid.

In yet another aspect, the present invention provides a two-pack system
35 for the preparation of a disinfectant composition, characterised in that one pack comprises a first aqueous solution comprising a lower aliphatic peracid, and the other pack comprises a second aqueous solution comprising hydrogen peroxide, a corrosion inhibitor and a hydrogen peroxide stabilizer

and/or peracid stabilizer.

The first aqueous solution preferably comprises a lower aliphatic peracid, such as peracetic acid, in an amount of from 2% to 10%, more preferably from 3% to 7%, by weight of the solution. The first aqueous solution may additionally comprise stabilizer(s) for the hydrogen peroxide and/or the peracid in the equilibrium solution, each relevant stabilizer being present in a preferred amount of from 20 to 10,000 ppm. Preferably both the peroxide and peracid are stabilized in the solution, giving a preferred combined stabilizer concentration of from 3000 to 6000 ppm. A suitable peracid stabilizer is dipicolinic acid and suitable peroxide stabilizers include phosphonic acids and salts thereof, e.g. the products sold by Monsanto under the trade mark "Dequest" such as hydroxyethylidenedimethylene phosphonate, diethylenetriaminepentamethylene phosphonate and ethylenediaminetetramethylene phosphonate and those stabilizers claimed in European patent application 0426949, especially cyclohexane-1,2-diaminotetramethylenephosphonic acid and salts thereof (CDTMP). It should be understood that the first solution is usually an equilibrium mixture of the relevant reactants and reaction products, as generally described in the paragraph bridging page 1 and page 2 above, and that the above specified amount of peracid indicates the amount of peracid per se in the solution. A preferred process for the preparation of dilute solutions of lower aliphatic peracids useful in the present invention is disclosed in PCT Patent Application No. WO 91/13058.

The hydrogen peroxide present in the second aqueous solution is preferably present as a dilute solution. In many embodiments the concentration of hydrogen peroxide present in the second aqueous solution is unlikely to be greater than about 5% w/w. Preferably, the concentration of hydrogen peroxide is from about 0.025% w/w to about 1% w/w, most preferably from about 0.05% w/w to about 0.5% w/w and in some embodiments from 0.05% w/w to 0.2% w/w. The function of the hydrogen peroxide in the second aqueous solution is to inhibit the growth of microbial contaminants in the solution.

The second aqueous solution preferably comprises from 0.1% to 5%, more preferably from 0.1% to 1%, by weight of the solution of a corrosion inhibitor. Preferably, the corrosion inhibitor is an alkali metal phosphate, most preferably a potassium phosphate. Dipotassium hydrogen orthophosphate (K_2HPO_4) is the most preferred corrosion inhibitor.

The second aqueous solution preferably comprises from about 0.1% to

about 2%, often 0.1% to 1%, more preferably up to 0.7% by weight of the solution of hydrogen peroxide stabilizer and/or peracid stabilizer. Preferably a hydrogen peroxide stabilizer is used. The preferred peroxide stabilizers are phosphonic acids and salts thereof, for example, those described
5 hereinabove as suitable for the first aqueous solution. A suitable peracid stabilizer is dipicolinic acid.

In particularly preferred embodiments, the second aqueous solution comprises from 0.025% to 1% w/w hydrogen peroxide, from 0.1% to 0.7% w/w of CDTMP and from 0.1 to 1% w/w of K_2HPO_4 .

10 According to certain preferred embodiments of the present invention, there is provided a two-pack system for the preparation of a disinfectant composition, characterised in that one pack comprises a first aqueous solution comprising 3% to 7% w/w peracetic acid, and the other pack comprises a second aqueous solution comprising from 0.025% to 1% w/w
15 hydrogen peroxide, from 0.1% to 0.7% w/w CDTMP and from 0.1% to 1% w/w of dipotassium orthophosphate.

Mixing of the first and second solutions give a disinfectant composition immediately after mixing comprising at least about 0.05% and generally not greater than about 1% by weight peracid. In many embodiments, the
20 mixture of the two solutions immediately after mixing comprises from about 0.1% to about 0.25% or from about 0.25% to about 0.5% by weight peracid. The mixture also desirably comprises from about 0.1% to about 5% corrosion inhibitor and from about 0.1% to about 1% peroxide stabilizer and/or peracid stabilizer. Such mixtures can often be obtained conveniently
25 by selecting a volume ratio of the first solution to the second solution which is often at least 1 : 5 and not usually greater than about 1 : 50, preferably from about 1 : 10 to about 1 : 30, taking into account the concentration of the components in each solution.

One or both of the aqueous solutions may contain other components
30 useful in disinfectant compositions, e.g. a triazole corrosion inhibitor and/or a wetting agent, though the presence of these components is not essential to obtain the advantages of the invention (indeed, such components may be slightly detrimental). One or both of the solutions may contain an indicator, such as, for example, methyl red, which undergoes a colour change to
35 indicate that the two solutions have been mixed together.

It will be appreciated that the compositions provided by the process of the present invention are not in equilibrium and that in the natural course of

events the peracid component of the composition will tend towards equilibrium. For example, the composition described in the paragraph immediately above this paragraph will begin to change within a relatively short period of time from mixing the first and second solutions together and
5 that as time passes the peracid concentration in the solution will reduce as it tends towards equilibrium. Normal equilibrium could be expected to be reached after about two days, assuming the peracid and/or peroxide does not decompose in that period.

The compositions of the present invention are particularly suitable for use
10 as medical disinfectants. Preferably, the compositions are used to disinfect medical equipment which has metal, e.g. aluminium, brass, copper and especially steel, components required to be disinfected. For example, the composition is particularly useful for disinfection of endoscopes. The present invention may have a further advantage over the prior art
15 compositions of Steris. The selected components of the invention composition interact to protect metal components, especially steel components, with regard to localised corrosion, eg pitting, as well as, if not better than, if molybdate, triazole and/or wetting agent were present. This is most surprising in light of the disclosure on page 4, lines 7 to 9, of Steris.

20 The present invention has the advantage of providing a dilute composition comprising a relatively high concentration of peracid. Furthermore, the process of the present invention enables a relatively longer shelf life for the separate aqueous solution than would be achieved if the composition was supplied per se.

25 The invention will now be further described, without limitation, with reference to the following examples:

Example 1. Preparation of Composition according to the Present Invention

A solution of 5% w/w peracetic acid, 20% w/w hydrogen peroxide, 8%
30 w/w acetic acid was diluted 14 times with a solution containing 0.1% w/w hydrogen peroxide, 1% w/w CDTMP (as supplied, 14% active w/w), 0.8% dipotassium hydrogen orthophosphate and 10 ppm 0.01% methyl red solution to form a solution containing 3,500ppm peracetic acid.

35 Example 2. Microbial Challenge Tests

A solution comprising 0.1% w/w hydrogen peroxide, 1% w/w CDTMP (as supplied, 14% active w/w) and 0.8% dipotassium hydrogen orthophosphate was tested in the German Society for Hygiene and Microbiology in vitro

tests (DGHM Standards for the Examination and Determination of chemical Disinfectant Processes, 1981. In vitro tests, Determination of the bacteriostatic and fungistatic efficiency). The test organisms used were bacteria Staphylococcus aureus, ATCC 6538, Pseudomonas aeruginosa,
5 ATCC 15442 and fungus Candida albicans ATCC 10231. The results of the tests showed inhibition of both bacterial and fungal growth in the solution.

A further challenge test was carried out against a solution comprising 0.4% w/w CDTMP (as 100%) and 0.8% dipotassium hydrogen orthophosphate
10 with 0.3% w/w hydrogen peroxide. As a control the same formulation but with no hydrogen peroxide was employed. 200ml of the solutions were challenged with 0.1ml cultures of bacteria Staphylococcus aureus, ATCC 6538 (cell count 18×10^8 cfu/ml) and Pseudomonas aeruginosa, ATCC 15442 (cell count 3.0×10^7 cfu/ml) and fungi Candida albicans ATCC
15 10231 (cell count 1.2×10^6 cfu/ml) at the start of the test, and with Aspergillus niger, IMI 149007 (cell count 2.9×10^7 spores/ml) after 7 days. The samples were stored for 6 months in screw top jars at ambient temperature and regularly analysed for surviving cultures. Surviving cultures were enumerated by dilution of 1ml samples of the solutions in
20 quarter-strength Ringers solution followed by culture as follows. For Staphylococcus aureus and Pseudomonas aeruginosa, 24hr @ 37°C in Tryptone Soya Broth, for Candida albicans, 72hr @ 37°C in Tryptone Soya Broth, for Aspergillus niger, until spores develop (5 - 10 days) @ 30°C in Malt Extract Agar. For the control solution (not according to the present
25 invention, the number of surviving colonies was between 1.3×10^6 and 2.4×10^7 cfu/ml, with the number being 4.7×10^6 cfu/ml after 6 months. For the solution according to the present invention, there were no surviving colonies, except for 24 hours after the addition of Aspergillus niger, when 4×10^3 cfu/ml was observed. After a further 24 hours storage, however,
30 there were no surviving colonies.

The results of the microbial challenge tests showed that the compositions according to the present invention gave good inhibition of microbial growth, and could give excellent resistance to microbial contamination over long
35 term storage.

Example 3. Chemical Stability Trials

4 samples of a solution suitable for use as a second aqueous solution in the

present invention (Formulation 1) containing 0.3% w/w hydrogen peroxide, 0.14% w/w CDTMP (as 100%), 0.8% dipotassium hydrogen orthophosphate, 0.3% benzotriazole and 10 ppm 0.01% methyl red solution were prepared. A further 4 samples containing an additional 0.2% benzotriazole (Formulation 2) were also prepared. Samples were stored for 1 month at each of ambient (ca. 20°C), 28°C, 32°C and 40°C and analysed for hydrogen peroxide content. The results of the analyses showed that for both solutions, there was no loss of hydrogen peroxide at any of the storage temperatures. The samples were also employed to produce compositions according to the present invention containing ca. 3,500ppm peracetic acid by 14 times dilution of a solution of 5% w/w peracetic acid, 20% w/w hydrogen peroxide and 8% w/w acetic acid. The solutions according to the present invention were analysed for peracetic acid and hydrogen peroxide content, stored for 5 days and then re-analysed for peracetic acid and hydrogen peroxide. The results are given below, and show excellent chemical stability.

Sample/ Time	1st Day		5th Day	
	% H ₂ O ₂	% PAA	% H ₂ O ₂	% PAA
Formulation 1				
Initial	2.16	0.37	2.15	0.24
1 month @ Temp:				
Ambient	2.03	0.37	2.21	0.26
28°C	2.01	0.34	2.10	0.24
32°C	2.05	0.34	2.11	0.26
40°C	2.04	0.40	2.10	0.30
Formulation 2				
Initial	1.98	0.35	1.99	0.22
1 month @ Temp:				
Ambient	2.06	0.39	2.08	0.25
28°C	2.08	0.35	2.11	0.26
32°C	2.12	0.29	2.11	0.28
40°C	2.06	0.35	2.02	0.26

Example 4. Corrosivity Test

A solution of 5% w/w peracetic acid, 20% w/w hydrogen peroxide, 8%

w/w acetic acid is diluted 25 times with a solution containing 0.3% w/w hydrogen peroxide, 0.14% w/w CDTMP (as 100%, < 25ppm chloride), 0.8% dipotassium hydrogen orthophosphate and 10 ppm 0.01% methyl red solution to form a disinfectant solution containing 2,000ppm peracetic acid.

5 Duplicate coupons of mild steel and stainless steel 316 are immersed for 72 hours in samples of the disinfectant solution at room temperature (average 20°C). The disinfectant solution is completely replaced daily with fresh solution. Examination of the coupons on completion of the trial shows only very slight localised corrosion of the coupons.

Claims

1. A process for the preparation of an aqueous disinfectant composition characterised in that the process comprises mixing a first aqueous solution comprising a lower aliphatic peracid with a second aqueous solution comprising hydrogen peroxide, a corrosion inhibitor and a hydrogen peroxide stabilizer and/or peracid stabilizer.
2. A disinfectant composition obtainable by a process comprising mixing a first aqueous solution comprising a lower aliphatic peracid with a second aqueous solution comprising hydrogen peroxide, a corrosion inhibitor and a hydrogen peroxide stabilizer and/or peracid stabilizer.
3. A two-pack system for the preparation of a disinfectant composition, characterised in that one pack comprises a first aqueous solution comprising a lower aliphatic peracid, and the other pack comprises a second aqueous solution comprising hydrogen peroxide a corrosion inhibitor and a hydrogen peroxide stabilizer and/or peracid stabilizer.
4. A process, composition or two-pack system as claimed in claim 1, 2 or 3, respectively, characterised in that the first aqueous solution comprises a (C₂-C₉) aliphatic peracid, such as peracetic acid, in an amount of from 2% to 10% by weight of the solution.
5. A process, composition or two-pack system as claimed in claim 4, characterised in that the first aqueous solution comprises a (C₂-C₉) aliphatic peracid, such as peracetic acid, in an amount of from 3% to 7% by weight of the solution.
6. A process, composition or two-pack system as claimed in claims 1, 2 or 3, respectively, or claim 4 or 5, characterised in that the second aqueous solution comprises from 0.1% to 5% by weight of the solution of a corrosion inhibitor.
7. A process, composition or two-pack system as claimed in claim 6, characterised in that the second aqueous solution comprises from 0.1% to 1% by weight of the solution of a corrosion inhibitor.

8. A process, composition or two-pack system as claimed in claim 6 or 7, characterised in that the corrosion inhibitor is an alkali metal phosphate.
9. A process, composition or two-pack system as claimed in claim 8, characterised in that the corrosion inhibitor is dipotassium hydrogen orthophosphate.
10. A process, composition or two-pack system as claimed in any one of claims 1 to 9, characterised in that the second aqueous solution comprises from 0.1% to about 2% by weight of the solution of hydrogen peroxide stabilizer and/or peracid stabilizer.
11. A process, composition or two-pack system as claimed in claim 10, characterised in that the second aqueous solution comprises from 0.1% to 0.7% by weight of the solution of hydrogen peroxide stabilizer and/or peracid stabilizer.
12. A process, composition or two-pack system as claimed in claim 10 or 11, characterised in that only a hydrogen peroxide stabilizer is used.
13. A process, composition or two-pack system as claimed in claim 10, 11 or 12, characterised in that the stabilizer(s) is/are phosphonic acids or salts thereof.
14. A process, composition or two-pack system as claimed in claim 13, characterised in that the hydrogen peroxide stabilizer is cyclohexane-1,2-diaminotetramethylenephosphonic acid or salts thereof.
15. A process, composition or two pack system as claimed in any preceding claim, characterised in that the second solution comprises less than about 5% w/w hydrogen peroxide
16. A process, composition or two pack system as claimed in claim 15, characterised in that the second solution comprises from about 0.025% w/w to about 1% w/w hydrogen peroxide.
17. A process, composition or two pack system as claimed in claim 15, characterised in that the second solution comprises from about 0.05%

w/w to about 0.2% w/w hydrogen peroxide.

18. A process, composition or two-pack system as claimed in any preceding claim, characterised in that the ratio of the volume of the first aqueous solution to the volume of the second aqueous solution is about 1 : 5 to about 1 : 50.
19. A process, composition or two-pack system as claimed in claim 18, characterised in that the ratio of the volume of the first aqueous solution to the volume of the second aqueous solution is about 1 : 10 to about 1 : 30.
20. A disinfectant composition, suitable for disinfecting medical equipment having metal components to be disinfected, characterised in that it comprises at least about 0.05% to about 0.25% by weight peracid, from about 0.1% to about 5% corrosion inhibitor and from about 0.1% to about 1% peroxide stabilizer and/or peracid stabilizer and wherein the peracid is not in an equilibrium state.
21. A disinfectant composition according to claim 20, characterised in that it comprises from 0.1% to about 0.25% or about 0.25% to about 0.5% by weight peracid and that the peracid is not in an equilibrium state.
22. A two-pack system for the preparation of a disinfectant composition, characterised in that one pack comprises a first aqueous solution comprising 3% to 7% w/w peracetic acid, and the other pack comprises a second aqueous solution comprising from 0.025% to 1% w/w hydrogen peroxide, from 0.1% to 0.7% w/w CDTMP and from 0.1% to 1% w/w of dipotassium orthophosphate:
23. A process, composition or two-pack system as claimed in any one of claims 1 to 22, characterised in that one or both of the two aqueous solutions comprises an indicator which undergoes a colour change when the solutions are mixed together.
24. A process, composition or two pack system according to any preceding claim, characterised in that it is suitable for disinfecting steel surfaces.

25. A process, composition or two pack system according to any preceding claim, characterised in that it gives reduced localised corrosion and pitting of steel.
26. Use of a composition as claimed in claim 2, or any one of claims 4 to 21 or 23 to 25, as a disinfectant.
27. Use as claimed in claim 26, characterised in that the disinfectant is suitable for disinfecting metal components of medical equipment.
28. Use as claimed in claim 27, characterised in that the medical equipment is an endoscope.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 94/00010

A. CLASSIFICATION OF SUBJECT MATTER

IPC5: A01N 37/16, A01N 59/00, A01N 25/22, A61L 2/18, C07C 409/24
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC5: A01N, A61L, C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO, A1, 9113058 (INTEROX CHEMICALS LIMITED ET AL.), 5 Sept 1991 (05.09.91), see page 9, first paragraph; the claims	1-3
A	--	4-28
X	US, A, 4297298 (F. CROMMELYNCK ET AL.), 27 October 1981 (27.10.81), see the claims; column 3, line 53, line 58 - line 66	1-3
A	--	4-28

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "B" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" documents referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

17 March 1994

19. 04. 94

Name and mailing address of the International Searching Authority/Authorized officer



European Patent Office, P.B. 5818 Patentaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2043, Tx. 31 651 epo nl.
Fax (+31-70) 340-3016

GERD STRANDELL

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 94/00010

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO, A1, 9113059 (PEROXIDOS DO BRASIL LTDA. ET AL.), 5 Sept 1991 (05.09.91), see the claims	1-5
A	--	6-28
X	DE, A, 2451904 (DAICEL LTD.), 7 May 1975 (07.05.75)	1-9
A	--	10-28
X	Chemical Abstracts, Volume 104, No 19, 12 May 1986 (12.05.86), (Columbus, Ohio, USA), US Food and Drug Administration, "Indirect food additives: adjuvants, production aids, and sanitizers; hydrogen peroxide; etc.", page 547, THE ABSTRACT No 167038w, Fed. Regist. 1986, 51 (42), 7438-7439	1-5
A	--	6-28
A	EP, A1, 0426949 (INTEROX CHEMICALS LIMITED), 15 May 1991 (15.05.91)	1-28
A	EP, A2, 357238 (STERIS CORPORATION), 7 March 1990 (07.03.90), see the claims	1-28
A	US, A, 4051058 (W.G. BÖWING ET AL.), 27 Sept 1977 (27.09.77), see column 2, line 18 - line 68; the claims	1-28

INTERNATIONAL SEARCH REPORT
Information on patent family members

28/01/94

International application No.

PCT/GB 94/00010

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 9113058	05/09/91	AU-A- 7249391 EP-A- 0517742 JP-T- 5504357	18/09/91 16/12/92 08/07/93
US-A- 4297298	27/10/81	CA-A- 1140150 EP-A,B- 0024219 FR-A- 2462425 JP-C- 1651850 JP-B- 3004545 JP-A- 56032453	25/01/83 25/02/81 13/02/81 30/03/92 23/01/91 01/04/81
WO-A1- 9113059	05/09/91	AU-B- 640466 AU-A- 7319791 EP-A- 0515486	26/08/93 18/09/91 02/12/92
DE-A- 2451904	07/05/75	FR-A,B- 2249878 JP-C- 909552 JP-A- 50071615 JP-B- 52038009	30/05/75 08/05/78 13/06/75 27/09/77
EP-A1- 0426949	15/05/91	AU-B- 635289 AU-A- 5906390 JP-A- 3153505 US-A- 5130053	18/03/93 16/05/91 01/07/91 14/07/92
EP-A2- 357238	07/03/90	NONE	
US-A- 4051058	27/09/77	AT-B- 349653 BE-A- 845228 CA-A- 1050877 CH-A- 620676 DE-A,C- 2536618 FR-A,B- 2321302 GB-A- 1563713 JP-C- 1353957 JP-A- 52025034 JP-B- 61014122 NL-A- 7608266 SE-B,C- 438424 SE-A- 7608459 AT-B- 350194 CA-A- 1050876 DE-A,C- 2616049 FR-A,B- 2321301 GB-A- 1561680 JP-C- 1441322 JP-A- 52025011 JP-B- 61010465 NL-A- 7608265 US-A- 4051059	25/04/79 16/02/77 20/03/79 15/12/80 24/02/77 18/03/77 26/03/80 24/12/86 24/02/77 17/04/86 18/02/77 22/04/85 17/02/77 10/05/79 20/03/79 27/10/77 18/03/77 27/02/80 30/05/88 24/02/77 29/03/86 18/02/77 27/09/77